2019 / 01

Следующая статья
DOI: 10.24075/vrgmu.2018.095

ОБЗОР

Лабораторная диагностика как основа медицины 5П

С. Н. Щербо, Д. С. Щербо
Информация об авторах

Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва, Россия

Для корреспонденции: Сергей Николаевич Щербо
ул. Островитянова, д. 1, г. Москва, 117997; ur.liam@sobrehchs

Статья получена: 30.01.2019 Статья принята к печати: 13.02.2019 Опубликовано online: 14.02.2019
|
  1. Щербо С. Н., Щербо Д. С. Медицина 5П: Прецизионная медицина. Медицинский алфавит. Современная лаборатория. 2015; (4): 5–10.
  2. Щербо С. Н., Щербо Д. С. Персонализированная медицина: монография в 7 томах. т. 1 Биологические основы. Москва. РУДН. 2016, 224 с.; т. 2 Лабораторные технологии. Москва. РУДН. 2017, 437 с.
  3. Раскина К. В., Мартынова Е. Ю., Перфильев А. В. и др. От персонализированной к точной медицине. Рациональная фармакотерапия в кардиологии. 2017; 13 (1): 69–79.
  4. Щербо С. Н., Щербо Д. С. Медицина 5П: мобильное здравоохранение. Медицинский алфавит. Современная лаборатория. 2017; 4 (28): 5–11.
  5. Годков М. А. Лабораторная диагностика в эпоху научно- технической революции. Закат или рассвет? Лабораторная служба. 2017; 6 (3): 5–8.
  6. Щербо С. Н., Тогузов Р. Т. Тенденции развития современной лабораторной медицины (лекция). Клиническая лабораторная диагностика. 2009; (3): 25–32.
  7. Snyder M. iPOP and its role in participatory medicine. Genome Med. 2014; (6): 6.
  8. Roberts NJ, Vogelstein JT, Parmigiani G, et al. The predictive capacity of personal genome sequencing. Sci Transl Med. 2012; 4 (133): 133ra58.
  9. Katz J. The silent wold of doctor and patient. Baltimore: Johns Hopkins University Press; 1983.
  10. Jain KK. Personalized Medicine. Waltham: Decision Resoures Inc., MA, USA; 1998.
  11. Personalized Medicine Coalition (PMC). The Case for Personalized Medicine. 2010.
  12. U.S. Food and Drug Administration (FDA) Department of Health and Human Services, Paving the Way for Personalized Medicine: FDA Role in a New Era of Medical Product Development. [(accessed on 10 January 2014)]; Available from: http:// www.fda.gov/downloads/ScienceResearch/SpecialTopics/ PersonalizedMedicine/UCM372421.pdf.
  13. Ginsburg GS, Willard HF. Genomic and Personalized Medicine. Elsevier Science. 2012; 1350 p.
  14. Schleidgen S, Klingler C, Bertram T, et al. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013; (14): 55.
  15. Nabipour I, Assadi M. Precision medicine, an approach for development of the future medicine technologies. ISMJ. 2016; (19): 167–84.
  16. O’Donnell PH, Danahey K, Jacobs M. Adoption of a clinical pharmacogenomics implementation program during outpatient care — initial results of the University of Chicago «1,200 Patients Project». Am J Med Genet C Semin Med Genet. 2014; (166C): 68–75.
  17. Juengist E, McGowan ML, Fishman JR, et al. From «Personalized» to «Precision» Medicine: The Ethical and Social Implications of Rhetorical Reform in Genomic Medicine. Hastings Cent Per. 2016; 46 (5): 21–33.
  18. Interlandi J. The Paradox of Precision Medicine. Sci Am. 2016; 314 (4): 24–25.
  19. Joyner MJ, Paneth N. Seven Questions for Personalized Medicine. JAMA. 2015; (55905): 2015–16.
  20. Collins FS, Varmus H. A New Initiative on Precision Medicine. N Engl J Med. 2015; (372): 793–95.
  21. Ziegelstein RC. Personomics. JAMA Intern. Med. 2015; (175): 888–89.
  22. Chochinov HM. Health care, health caring, and the culture of medicine. Curr Oncol. 2014; (21): e668–e669.
  23. Gupte AA, Hamilton DJ. Molecular Imaging and Precision Medicine. Cardiology. 2016; (133): 178–80.
  24. Mason-Suares H, Sweetser D, Lindeman N, et al. Training the Future Leaders in Personalized Medicine. J Pers Med. 2016; 6 (1): 1.
  25. Smoller J, Karlson E, Green R, et al. An eMERGE Clinical Center at Partners Personalized Medicine. J Pers Med. 2016; 6 (1): 5.
  26. Hricak H. Oncologic imaging: a guiding hand of personalized cancer care. Radiology. 2011; (259): 633–40.
  27. Le Tourneau C, Delord JP, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; (16): 1324–34.
  28. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013; 31 (15): 1803–05.
  29. Bettegowda C, Sausen M, Leary R.J, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; (6): 224ra24.
  30. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2014. Annals of Oncology. 2014; (25): 1650–56.
  31. Attard G, Beltran H. Prioritizing precision medicine for prostate cancer. Annals of Oncology. 2015; (26): 1041–42.
  32. Amin Al, Olama A, Benlloch S, et al. Risk analysis of prostate cancer in PRACTICAL, a multinational consortium, using 25 known prostate cancer susceptibility loci. Cancer Epidemiology, Biomarkers & Prevention. 2015; (24): 1121–29.
  33. Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study. European Urology. 2014; (66): 489–99.
  34. Bechis SK, Otsetov AG, Ge R, et al. Age and obesity promote methylation and suppression of 5-alpha reductase 2—Implications for personalized therapy in benign prostatic hyperplasia. Journal of Urology. 2015; (194): 1031–37.
  35. Prakash K, Pirozzi G, Elashoff M, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays. Proceedings of the National Academy of Sciences of the United States of America. 2002; (99): 7598–603.
  36. Helfand BT, Hu Q, Loeb S, et al. Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility. Journal of Urology. 2013; (189): 845–48.
  37. Тофило М. А., Егорова Е. Н. МикроРНК, регулирующие адипогенез при сахарном диабете 2-го типа. Здоровье и образование в XXI веке. 2017; 19 (3): 108–11.
  38. Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult–onset diabetes and their association with outcomes: a data–driven cluster analysis of six variables. The Lancet Diabetes Endocrinology. 2018; 6 (5): 361–69.
  39. Дедов И. И., Титович Е. В., Кураева Т. Л. и др. Взаимосвязь генетических и иммунологических маркеров у родственников больных СД 1 типа. Сахарный диабет. 2008; (4): 46–50.
  40. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring study. Diabetes. 2000; (49): 2201–17.
  41. Shields BM, Longergan M, Dennis J, et al. Patient characteristics are associated with treatment response to second line glucose lowering therapy: a MASTERMIND study abstracts of 51st EASD annual meeting. Diabetologia. 2015; 58 (Suppl 1): S405.
  42. Chakera AJ, Steele AM, Gloyn AL, et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care. 2015; (38): 1383–92.
  43. Shields BM, McDonald TJ, Ellard S, et al. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia. 2012; (55): 1265–72.
  44. Pearson ER, Pruhova S, Tack CJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia. 2005; (48): 878–85.
  45. Tan Lin, Jiang T, Tan Lan, et al. Toward precision medicine in neurological diseases. Ann Transl Med. 2016; 4. (6): 104.
  46. Bu L-L, Yang K, Xiong W.-X, et al. Toward precision medicine in Parkinson s disease. Ann Transl Med. 2016; 4 (2): 26.
  47. Vieta E. Personalised medicine applied to mental health: Precision psychiatry. Rev Psiquiatr Salud Ment. 2015; 8 (3): 117–18.
  48. Fernandes BS, Williams LM, Steiner J, et al. The new field of “precision psychiatry”. BMC Med. 2017; (15): 80.
  49. Stephan KE, Bach DR, Fletcher PC, et al. Charting the landscape of priority problems in psychiatry, part 1: classification and diagnosis. Lancet Psychiatry. 2016; 3 (1): 77–83.
  50. Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014; 171 (4): 395–7.
  51. Andersson G, Titov N. Advantages and limitations of Internet-based interventions for common mental disorders. World Psychiatry. 2014; 13 (1): 4–11.
  52. Carvalho AF, Kohler CA, Brunoni AR, et al. Bias in peripheral depression biomarkers. Psychother Psychosom. 2016; 85 (2): 81–90.
  53. Marzano L, Bardill A, Fields B, et al. The application of mHealth to mental health: opportunities and challenges. Lancet Psychiatry. 2015; 2 (10): 9442–48.
  54. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014; 171 (12): 1278–86.
  55. Passalaqua G, Canonica GW. AIT (allergen immunotherapy): a model for the “precision medicine”. Clin Mol Allergy. 2015; (1): 24.
  56. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015; 8 (1): 17.
  57. Agusti A. The path to personalised medicine in COPD. Thorax. 2014; (69): 857–64.
  58. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015; (135): 299–310.
  59. Zazzu V, Regierer B, Kuhn A, et al. IT Future of Medicine: from molecular analysis to clinical diagnosis and improved treatment. N Biotechnol. 2013; 30 (4): 362–65.